Understanding the pathogenesis of chronic lymphocytic leukemia to develop novel targeted therapies

Dr. Martina Seiffert

Chronic lymphocytic leukemia

© dkfz.de

B cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the Western World. It is characterized by the expansion of mature B lymphocytes and shows a heterogeneous clinical course, which can be partly explained by specific genomic aberrations or B cell receptor characteristics. Recent therapeutic advances have led to very good initial response rates. However, a large proportion of patients eventually relapse, and CLL remains an incurable disease. Despite extensive efforts, the underlying pathomechanism of CLL is still largely unknown and genotype specific and targeted therapies are not available. Therefore, the goal of our ongoing research activities is to establish a better understanding of the pathomechanism of CLL and to translate these findings into novel and targeted therapeutic approaches.

Contact

© dkfz.de

Dr. Martina Seiffert
Team Leader
E-Mail: m.seiffert@dkfz.de
Tel.: +49-6221-42-4586
Publications
Collaboration Partners

to_top